2024 National Conference Resources

• Benign, Malignant, and Somewhere In Between
  Ashfaq Marghoob, MD
• Cutaneous Immunology 
  Andrew Blauvelt, MD, MBA
• Where the Drugs Fit In
  Andrew Blauvelt, MD, MBA
• Interesting Cases in Psoriasis/Mimics
  Jennifer Cather, MD; Melodie Young, MSN, A/GNP-c, FSDNP
• Case Studies & Posters
  Moderator: Lakshi Aldredge, MSN, ANP-BC, DCNP
• Acne and Rosacea Update
  Heather Roebuck, DNP, FNP-BC, FAANP
• Hidradenitis Suppurativa Update
  Heather Roebuck, DNP, FNP-BC, FAANP
• Non-Melanoma Cutaneous CA Update
  Victor Czerkasij, DNP, FNP-C
• Women’s Health and Dermatology Across the Lifespan
  Kamila Smith, MD, FACOG, NCMP
• Dermpath Tips
  Whitney High, MD, JD, MEng
• What's New in Derm
  Matthew Zirwas, MD

• You Think You Know the Skin
  

  Whitney High, MD, JD, Meng
• Dermatitis
  Matthew Zirwas, MD
• Connective Tissue Disorders
  Melissa Costner, MD, FAAD
• Pruritic
  Matthew Zirwas, MD
• How to Approach Your Pediatric Patients and Their Families
  Peggy Vernon, RN, MA, CPNP, DCNP, FAANP
• Skin of Color
  Candrice Heath, MD
• Understanding Clinical Research
  Wendy Cantrell, DNP, CRNP
• Mastering Dermatology Coding and Billing: Essential Tips for Nurse Practitioners
  Leslie Boles, BA, CCS, CPC, CPMA, CHC, CPC-I, CRC
• Hot Topics in Dermatology: Business, Ethics, and Scope of Practices
  Melodie Young, MSN, A/GNP-c, FSDNP; Kathleen Haycraft, DNP, FNP/PNP-BC, DCNP,FAANP, FSDNP; Beth Haney, DNP, FNP-C, FAANP, FAAN
• Cosmetic Update
  Beth Haney, DNP, FNP-C, FAANP, FAAN
• Test Your Skills
  Melodie Young, MSN, A/GNP-c, FSDNP; Kathleen Haycraft, DNP, FNP/PNP-BC, DCNP, FAANP, FSDNP

Posters

Dermoscopy as a Tool to Assess Clinical Response to Talimogene Laherparepvec (TVEC) in Metastatic Melanoma

Once-Daily Roflumilast Cream 0.15% for Atopic Dermatitis: Pooled Results FromINTEGUMENT-1/2 Phase 3 Trials

Delivering Culturally Relevant Medication Education to Improve Safety in Topical Steroid Use within a Dermatology Private Practice in New York City

Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis

Reduction in Pruritus Across Indications in Phase 3 Trials of Topical Roflumilast

Safety of Lebrikizumab in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: Integrated Analysis From 10 Clinical Trials

Lebrikizumab Provides Stable Itch Response With No or Minimal Fluctuations Up to One Year in Patients With Atopic Dermatitis

Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients With Skin of Color and Moderate-to-Severe Atopic Dermatitis: An Interim Analysis of the Open-Label Phase 3b Trial, ADmirable

Clinical Measures of Improvement in Atopic Dermatitis Are Correlated With Reductions in Relevant Biomarkers in Patients Treated With Lebrikizumab

Improvements on Patient-Reported Outcome (PRO) Measures With 24 Weeks of Amlitelimab Treatment in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Trial (STREAM-AD)

Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis: 52-week results from a Phase 2b trial (STREAM-AD) ID: 11 Copies

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in plaque psoriasis: 3-year Psoriasis Area and Severity Index (PASI) outcomes in the long-term extension of the phase 3 POETYK PSO-1 and PSO-2 trials

Efficacy of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in scalp psoriasis by baseline Psoriasis Area and Severity Index (PASI) and baseline body surf ace area (BSA): a subanalysis of the phase 3 clinical trial data

A PSORIATIC ARTHRITIS ASSESSMENT AND TREATMENT PARADIGM